RecruitingNot ApplicableNCT07266584

Restoration of Central Vision With PRIMA in Patients With Photoreceptor Degeneration

Restoration of Central Vision With the PRIMA Products in Patients With Photoreceptor Degeneration


Sponsor

Science Corporation

Enrollment

5 participants

Start Date

Apr 22, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

The objective of this study is to evaluate the efficacy and safety of the PRIMA Products in participants with inherited retinal degeneration affecting the macula (including but not limited to Stargardt disease, and Retinitis Pigmentosa). Eligible participants will be implanted with the PRIMA Stim implant. The participants will be assessed with various visual function and functional vision tests at defined timepoints throughout the clinical investigation with the PRIMA Products. The purpose of this study is to gather enough clinical data to support the clinical evaluation required for the continuous development to improve the PRIMA Products.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a medical device called PRIMA Products for people with inherited retinal degeneration, retinitis pigmentosa (rp), and other related conditions. The study is currently recruiting participants at 1 location.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEPRIMA Products

Implantation of PRIMA, Vision training, follow up


Locations(1)

Sydney Eye Hospital

Sydney, New South Wales, Australia

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07266584


Related Trials